The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -0.30 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as ANAPTYSBIO, INC reports it. History and quarterly detail are in the app.
- Anaptys Bio Generated Anti PD1Jemperli Dostarlimab$258.0M
- License$9.5M
- Transaction Service$200K
Leadership changes
From ANAPTYSBIO, INC's own filings, the day they're filed.
- Christopher M. Murphy · Chief Financial Officer · appointmenteff. 2026-05-11
- Owen Hughes · director · appointmenteff. 2026-05-11
- J. Anthony Ware · directors · departureeff. 2026-04-20
Latest filings
- 8-K · Company announcement2026-05-29
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about ANAPTYSBIO, INC, every answer cited🔒
- The Intelligence Brief — added when ANAPTYSBIO, INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.